FDA Proposes Restrictions on Compounding Popular Diabetes and Weight-Loss Drugs

The U.S. Food and Drug Administration has put forth a proposal to remove certain GLP-1 receptor agonists, including semaglutide and tirzepatide, from its 503B Bulks List. This measure aims to restrict compounding pharmacies from utilizing these active pharmaceutical ingredients in custom drug preparations. The agency states this action is intended to enhance patient safety and ensure drug quality.